Published in Proc Natl Acad Sci U S A on August 20, 1996
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia | NCT03323437
The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull (2009) 6.03
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull (2009) 3.82
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci (2011) 3.23
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A (1997) 3.00
Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry (2007) 2.94
Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. Nat Neurosci (2015) 2.89
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
Do patients with schizophrenia exhibit aberrant salience? Psychol Med (2008) 2.28
The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg (2009) 2.24
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) (2004) 2.06
Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron (2012) 1.99
Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull (2010) 1.97
A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron (2010) 1.96
The environment and susceptibility to schizophrenia. Prog Neurobiol (2010) 1.94
European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry (2010) 1.92
The computational anatomy of psychosis. Front Psychiatry (2013) 1.84
The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res (2008) 1.84
Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology (2011) 1.78
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A (2001) 1.77
Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry (2013) 1.68
Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology (2008) 1.64
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci (2004) 1.61
Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res (2009) 1.60
Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull (2008) 1.59
Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int J Dev Neurosci (2011) 1.56
GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology (2011) 1.55
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des (2009) 1.51
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) (2003) 1.49
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci (2011) 1.49
A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull (2008) 1.49
Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. Learn Mem (2002) 1.48
Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology (2010) 1.47
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull (2009) 1.45
Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J (2007) 1.44
A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet (2007) 1.43
Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci (2004) 1.39
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain (2008) 1.37
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Gene-environment interplay between cannabis and psychosis. Schizophr Bull (2008) 1.34
Rethinking schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci (2013) 1.33
The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology (2007) 1.31
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl (2007) 1.31
The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev (2009) 1.30
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology (2007) 1.30
Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem (2009) 1.29
Inhibition of NMDARs in the Nucleus Reticularis of the Thalamus Produces Delta Frequency Bursting. Front Neural Circuits (2009) 1.28
What we know: findings that every theory of schizophrenia should explain. Schizophr Bull (2009) 1.27
Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A (2000) 1.25
Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One (2010) 1.24
Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia? Schizophr Bull (2007) 1.23
Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) (2004) 1.22
Reinforcement and reversal learning in first-episode psychosis. Schizophr Bull (2008) 1.22
Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology (2009) 1.20
Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry (2009) 1.18
Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci (2011) 1.18
Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology (2009) 1.15
The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect (2010) 1.15
Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse (2010) 1.15
Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem (2010) 1.14
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull (2010) 1.13
Probabilistic learning and inference in schizophrenia. Schizophr Res (2011) 1.12
Motor coordination deficits in mice lacking RGS9. Brain Res (2007) 1.11
Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull (2009) 1.10
Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) (2007) 1.08
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull (2008) 1.07
Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology (2009) 1.06
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry (2013) 1.05
A classification of sociomedical health indicators: perspectives for health administrators and health planners. Int J Health Serv (1976) 1.04
Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) (2003) 1.03
Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology (2008) 1.03
Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology (2013) 1.02
Prevention and schizophrenia--the role of dietary factors. Schizophr Bull (2010) 1.01
Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging (2003) 1.01
Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) (2009) 1.01
A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci (2008) 1.01
Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) (2009) 1.01
Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry (2012) 1.00
The extended amygdala and the dopamine system: another piece of the dopamine puzzle. J Neuropsychiatry Clin Neurosci (2003) 1.00
Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain (2013) 1.00
Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. Mol Psychiatry (2013) 0.99
Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology (2013) 0.99
Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field. Neuropsychopharmacology (2013) 0.98
Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex (2008) 0.98
Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry (2010) 0.97
Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull (2012) 0.97
Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov (2012) 0.97
The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. Neuropsychopharmacology (2011) 0.97
Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia. Psychopharmacology (Berl) (2008) 0.96
Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology (Berl) (2009) 0.96
Reviewing the ketamine model for schizophrenia. J Psychopharmacol (2013) 0.96
Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia. Int J Neuropsychopharmacol (2011) 0.95
Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Hum Mol Genet (2013) 0.95
Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology (2010) 0.95
Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry (2012) 0.95
Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings. Biol Psychiatry (2010) 0.95
Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci (2011) 0.94
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res (2009) 0.93
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry (1987) 8.81
Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry (1991) 5.36
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry (1992) 2.84
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci (1995) 2.74
Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry (1991) 2.55
The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1988) 2.51
Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci (1994) 2.31
The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther (1966) 2.18
Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 2.08
Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol (1971) 2.08
Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science (1986) 2.00
6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci (1994) 1.70
Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse (1994) 1.68
No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res (1995) 1.66
Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) (1987) 1.60
SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med (1995) 1.56
The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem (1996) 1.55
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) (1989) 1.55
D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry (1990) 1.42
Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A (1994) 1.30
The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. Biol Psychiatry (1970) 1.30
Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia (1975) 1.24
Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science (1977) 1.24
Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo. J Pharm Pharmacol (1978) 1.19
Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature (1978) 1.19
Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull (1990) 1.17
Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci U S A (1989) 1.15
Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse (1992) 1.10
Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm Gen Sect (1993) 1.03
Kinetic properties of the accumulation of 3H-raclopride in the mouse brain in vivo. Naunyn Schmiedebergs Arch Pharmacol (1989) 1.00
Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry (1994) 0.99
D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry (1994) 0.97
Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res (1993) 0.94
The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry (1991) 0.93
Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain. Biochem Pharmacol (1973) 0.89
In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. Eur J Pharmacol (1983) 0.87
The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res (1992) 0.85
Synergism between D1 and D2 dopamine receptors in the inhibition of the evoked release of [3H]GABA in the rat prefrontal cortex. Neuroscience (1991) 0.84
Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med (1992) 0.84
Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-benztropine in primates. Neuropsychopharmacology (1993) 0.82
Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide. J Med Chem (1988) 0.82
The relationship between the stimulation of dopamine synthesis and release produced by amphetamine and high potassium in striatal slices. J Neurochem (1980) 0.81
Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur J Pharmacol (1981) 0.81
Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices. J Pharmacol Exp Ther (1977) 0.81
Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J Neural Transm Suppl (1983) 0.81
Reevaluation of the mesolimbic hypothesis of antipsychotic drug action. Schizophr Bull (1995) 0.80
The development of a Clinician-Administered PTSD Scale. J Trauma Stress (1995) 22.71
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med (1990) 16.54
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry (1989) 6.80
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry (1995) 5.34
Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. Am J Psychiatry (1997) 5.13
Hippocampal volume reduction in major depression. Am J Psychiatry (2000) 5.04
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry (1990) 3.57
Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse--a preliminary report. Biol Psychiatry (1997) 3.39
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
The cellular neurobiology of depression. Nat Med (2001) 3.19
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 3.07
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 3.01
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 2.92
Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry (1993) 2.89
Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 2.88
Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1999) 2.78
Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science (1999) 2.76
Neural correlates of exposure to traumatic pictures and sound in Vietnam combat veterans with and without posttraumatic stress disorder: a positron emission tomography study. Biol Psychiatry (1999) 2.62
A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry (2001) 2.58
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry (1999) 2.35
Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci (1994) 2.31
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry (1998) 2.30
Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry (2000) 2.27
Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry (1999) 2.27
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry (1991) 2.17
Childhood physical abuse and combat-related posttraumatic stress disorder in Vietnam veterans. Am J Psychiatry (1993) 2.16
Exploring the degree of concordance of coded and textual data in answering clinical queries from a clinical data repository. J Am Med Inform Assoc (2000) 2.10
Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol (1999) 2.09
Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry (1994) 2.04
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry (2011) 2.03
Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry (1998) 2.02
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry (1999) 1.97
X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet (1994) 1.97
Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse (1996) 1.97
One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction (2000) 1.93
Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry (1993) 1.88
Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Am J Psychiatry (1996) 1.87
Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. Arch Gen Psychiatry (1989) 1.86
Activation of human prefrontal cortex during spatial and nonspatial working memory tasks measured by functional MRI. Cereb Cortex (1996) 1.82
Deficits in short-term memory in posttraumatic stress disorder. Am J Psychiatry (1993) 1.81
Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A (1980) 1.78
Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med (1995) 1.77
Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab (2000) 1.77
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse (1996) 1.75
Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol (1995) 1.70
Toward a neurobiology of delusions. Prog Neurobiol (2010) 1.70
5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol (2000) 1.67
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry (1989) 1.66
COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry (2008) 1.63
Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry (1997) 1.59
Recurrent intracerebral hemorrhage. Neurology (1997) 1.59
Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry (2000) 1.58
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry (1990) 1.56
Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry (1993) 1.56
SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med (1995) 1.56